Ex-InterMune exec sued by feds; Puma begins PhIII breast cancer trial;

@FierceBiotech: From FierceBiotechIT.com: IMS Health scoops up Incential Software. Report | Follow @FierceBiotech

@RyanMFierce: Sanofi seeks compelling case for next-generation Lantus in diabetes war. Article | Follow @RyanMFierce

@EmilyMFierce: Spinal muscular atrophy patients could benefit from new drug. Story | Follow @EmilyMFierce

> The U.S. Securities and Exchange Commission has sued ex-InterMune ($ITMN) Controller Bruce Tomlinson for allegedly disclosing secret information about the drug Esbriet to a former business associate. Story

> Boston-based Follica may have found the answer to baldness. News

> Eli Lilly ($LLY) has so far created 7 Project Focused Companies, or PFCs, in its Capital Funds Portfolio. Blog

> Puma Biotechnology ($PBYI) has begun a Phase III clinical trial of its lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer. Release

Medical Device News

@FierceMedDev: Don't forget to nominate! We're looking for 15 of the fiercest device and diagnostics developers. Info | Follow @FierceMedDev

@DamianFierce: Study: Medical devices spur complications for kids. More | Follow @DamianFierce

@MarkHFierce: Teleflex has long pursued M&A involving small startups with promising tech. This time, it's Israel's Eon Surgical. Article | Follow @MarkHFierce

 @MichaelGFierce: BioFire scores CE mark for sepsis blood Dx. Item | Follow @MichaelGFierce

> Bayer closes $1.1B birth control device deal. Article

> Mobisante reels in $4.2M to market its ultrasound mobile app. Story

> Quest allies with Hologic in women's health Dx deal. News

Pharma News

@FiercePharma: Mini-Pfizer? Endo to cut 700 jobs, review asset sales in refocus on core pharma biz. Yesterday's story | Follow @FiercePharma

@EricPFierce: Is Teva and its generic of Avandia the big winner in today's vote? More | Follow @EricPFierce

@CarlyHFierce: The FDA advisory panel reached a verdict on Avandia yesterday. How would you have voted? Story | Follow @CarlyHFierce

> Battle of weight-loss drugs begins as Arena launches Belviq next week. Article

> Sanofi uses multi-pronged strategy to defend its place in diabetes market. Story

> Reuters: Forest, Icahn negotiate to avoid 3rd proxy battle. More

And Finally… Despite the lingering economic crisis, the French biotech sector is showing some signs of life. More

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

Scorpion is working on precision oncology 2.0, which includes making better drugs for known targets, hit undruggable targets and discover new targets.

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.